Ken Griffin Revolution Medicines, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$36.92 - $47.94 $3.81 Million - $4.95 Million	103,300 Added 853.72%	115,400 $5.23 Million
Q2 2024 Aug 14, 2024	BUY	$30.14 - $40.68 $33,154 - $44,748	1,100 Added 10.0%	12,100 $469,000
Q1 2024 May 15, 2024	SELL	$26.56 - $33.55 $212,480 - $268,400	-8,000 Reduced 42.11%	11,000 $354,000
Q4 2023 Feb 14, 2024	BUY	$18.35 - $34.12 $75,235 - $139,892	4,100 Added 27.52%	19,000 $544,000
Q3 2023 Nov 14, 2023	BUY	$25.17 - $35.05 $166,122 - $231,329	6,600 Added 79.52%	14,900 $412,000
Q1 2023 May 15, 2023	BUY	$20.76 - $30.09 $62,280 - $90,270	3,000 Added 56.6%	8,300 $179,000
Q4 2022 Feb 14, 2023	BUY	$17.68 - $25.53 $93,704 - $135,309	5,300 New	5,300 $126,000

267

161M

260K

620K

Ticker RVMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,697,600
Market Cap $5.07B
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.